Depression pathogenesis and treatment: what can we learn from blood mRNA expression?

BMC Med. 2013 Feb 5;11:28. doi: 10.1186/1741-7015-11-28.

Abstract

Alterations in several biological systems, including the neuroendocrine and immune systems, have been consistently demonstrated in patients with major depressive disorder. These alterations have been predominantly studied using easily accessible systems such as blood and saliva. In recent years there has been an increasing body of evidence supporting the use of peripheral blood gene expression to investigate the pathogenesis of depression, and to identify relevant biomarkers. In this paper we review the current literature on gene expression alterations in depression, focusing in particular on three important and interlinked biological domains: inflammation, glucocorticoid receptor functionality and neuroplasticity. We also briefly review the few existing transcriptomics studies. Our review summarizes data showing that patients with major depressive disorder exhibit an altered pattern of expression in several genes belonging to these three biological domains when compared with healthy controls. In particular, we show evidence for a pattern of 'state-related' gene expression changes that are normalized either by remission or by antidepressant treatment. Taken together, these findings highlight the use of peripheral blood gene expression as a clinically relevant biomarker approach.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Depression / drug therapy*
  • Depression / physiopathology*
  • Humans
  • Inflammation / physiopathology
  • Microarray Analysis
  • Neuronal Plasticity / physiology
  • Receptors, Glucocorticoid / metabolism
  • Transcriptome*

Substances

  • Receptors, Glucocorticoid